Nib treatment may initiate MET pathway activation, further supporting the earlier use of MET and EGFR inhibitors in combination for treating malignant GBM. Added fileAdditional file 1: Supplementary information like Supplementary Methods, 1 Supplementary Table, 4 Supplementary Figures and Supplementary Reference.Abbreviations GBM: glioblastoma; HGF: hepatocyte development aspect; PDX: models patient derived xenograft models; TCGA: the Cancer Genome Atlas Network; FISH: fluorescence in situ hybridization; TMZ: temozolomide; PCA: principle Element Analysis; IPA: ingenuity Pathway Analysis; NSCLC: non little cell lung cancer; MGMT: O6-methylguanine-DNA-methyltransferase. Authors’ contributions JJ and DN performed molecular and cellular research. MLA performed microarray and qPCR evaluation. KL, JJ and QX performed in vivo efficacy study and information analysis. SM collected GBM patient specimens. MB, KT, FMM, GVW, MEB, and QX performed study design and style and information interpretation. QX, MEB, and SM wrote the paper. All authors read and authorized the final manuscript. Author details 1 Molecular Oncogenesis and Targeted Therapy, Laboratory of Molecular Oncology, Van Andel Investigation Institute, 333 Bostwick AVE NE, Grand Rapids, MI 49503, USA. 2 Laboratory of Molecular Oncology, Van Andel Analysis Institute, Grand Rapids, MI, USA. 3 Division of Transfusion Medicine, Infectious Disease and Immunogenetics Section, Clinical Center, Trans-National Institutes of Wellness Center for Human Immunology, National Institutes of Overall health, Bethesda, MD, USA. 4 Department of Oncology, Johns Hopkins University, Baltimore, MD, USA. five Departments of Neurosurgery and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. six Vertex Pharmaceutical Inc., Boston, MA, USA. 7 Woodland Pharmaceuticals, Shrewsbury, MA, USA. 8 Study Branch, Sidra Medical and Study Center, Doha, Qatar. 9 Translational Genomics Research Institute, Phoenix, AZ, USA. Acknowledgements We thank Drs. Jann Sarkaria (Mayo Clinic) for offering GBM PDX models for this study; Drs. Ena Wang (Department of Transfusion Medicine, Clinical Center, NIH) and Kyle Furge (Van Andel Investigation Institute) for recommendations and instructions on microarray and bio-informatics analysis. We thank David Nadziejka for technical editing with the manuscript. This work was supported by the American Brain Tumor Association Discovery Grant 2013 and the Steven M. Coffman Charitable Fund (QX), Van Andel Institute (GVW and QX); NIH/ NCI R01 CA123451, Fund for Health-related Research and Education, Wayne State University School of Medicine, Strategic Research Initiative Grant, Karmanos Cancer Institute (SM); NIH/NCI U01CA168397 along with the Ben and Catherine Ivy Foundation (MEB).SOST Protein MedChemExpress Compliance with ethical guidelines Competing interests The authors declare that they’ve no competing interestsJohnson et al.FGF-19 Protein Storage & Stability J Transl Med (2015) 13:Page 12 ofReceived: 12 June 2015 Accepted: 9 September 2015 18.PMID:25016614 19.References 1. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21(8):16246. two. Rao JS. Molecular mechanisms of glioma invasiveness: the function of proteases. Nat Rev Cancer. 2003;three(7):48901. 3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and much more. Nat Rev Mol Cell Biol. 2003;four(12):9155. four. Network CGAR. Complete genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061.